NCT02917200 is a Phase 1 clinical trial of Moxifloxacin in Healthy Subjects, sponsored by Da Volterra.

Who is sponsoring NCT02917200?

NCT02917200 is sponsored by Da Volterra.

What drugs are being tested in NCT02917200?

Interventions in NCT02917200: Moxifloxacin, DAV132, Negative control.

What condition does NCT02917200 study?

NCT02917200 studies Healthy Subjects.

Is NCT02917200 still recruiting?

NCT02917200 is currently completed. Last updated 12 September 2017.

Last reviewed 2017-09-12 · How we verify

NCT02917200

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy Study of Different DAV132 Dose Regimens in Healthy Volunteers

Completed Phase 1 Last updated 12 September 2017

What this trial tests

Phase 1 trial testing Moxifloxacin in Healthy Subjects in 150 participants. Completed in 2 December 2016.

Timeline

11 May 2016

Primary endpoint
2 December 2016

2 December 2016

Quick facts

Lead sponsor	Da Volterra
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	150
Start date	11 May 2016
Primary completion	2 December 2016
Estimated completion	2 December 2016
Sites	1 location across France

Drugs / interventions tested

Moxifloxacin (moxifloxacin) — full drug profile →
DAV132
Negative control — full drug profile →

Conditions studied

Healthy Subjects — all drugs for Healthy Subjects →

Sponsor

Da Volterra

Who can join

Adults 18 to 60, any sex, with Healthy Subjects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate whether different DAV132 dose regimens are safe and effective for capturing fecal residues of moxifloxacin in healthy volunteers.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy.
Thomas AM, Fidelle M, Routy B, Kroemer G, et al · · 2023 · cited 100× · PMID 37365438 · DOI 10.1038/s41571-023-00785-8
Optimization of an Assay To Determine Colonization Resistance to Clostridioides difficile in Fecal Samples from Healthy Subjects and Those Treated with Antibiotics.
Harris HC, Best EL, Normington C, Saint-Lu N, et al · · 2020 · cited 5× · PMID 33139292 · DOI 10.1128/aac.01401-20

Verify or expand the search:

Other trials of Moxifloxacin

Trials testing the same drug.

NCT07513207 — A Study in Healthy People to Test How Vicadrostat Affects the Heart · Phase 1 · not yet recruiting
NCT07422298 — A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants · Phase 1 · recruiting
NCT07305831 — A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012) · Phase 1 · active not recruiting
NCT07272629 — A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participan · Phase 1 · recruiting
NCT07229157 — Effect of Maridebart Cafraglutide on the Heart's Electrical Activity · Phase 1 · active not recruiting

Other recruiting trials for Healthy Subjects

Currently open trials in the same condition.

NCT07222020 — Phase 1 Study of Intravaginal KB15A · Phase 1 · recruiting
NCT07350538 — The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL · NA · active not recruiting
NCT07304791 — This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and P · Phase 1 · recruiting
NCT07059858 — Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities · recruiting
NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting

Other Da Volterra trials

Trials by the same sponsor.

NCT03710694 — Safety and Efficacy of DAV132 in Patients at High-Risk for Clostridium Difficile Infection (CDI) · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02917200 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Da Volterra
Last refreshed: 12 September 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02917200.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing